Our science redefines the possibilities

 Our Approach

The alternative pathway: its dysregulation can drive pathogenesis in rare diseases

In numerous rare diseases, the complement alternative pathway (AP) is activated by an artificial surface, the body's own proteins and cells, or bacterial and viral surfaces. In these settings, dysregulation of the AP activity induces inflammation and cellular destruction, which can further exacerbate the symptoms of chronic rare diseases. NovelMed’s strategy to selectively target the AP has led to the development of several first-in-class antibody-based drugs that have shown remarkable results in disease models and in Phase I clinical trials.
Our lead drug candidates prevent the formation of C3a/C3b, C5a/C5b, and MAC via the AP. The drugs have no effect on the Classical Pathway.

NovelMed has a portfolio of innovative antibodies with the potential to treat several different orphan and non-orphan diseases. Talk to us about your interests. Given the multitude of inflammatory-mediated diseases, our platform of antibodies may be able to satisfy your strategic or investment objectives